BRIEF—Zevra sells Miplyffa-linked PRV for $150 million

Rare disease-focused biopharma Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $150 million.

The PRV was granted to Zevra in September 2024 following approval by the US Food and Drug Administration of Miplyffa (arimoclomol), which is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C in adult and pediatric patients two years of age and older.

LaDuane Clifton, Zevra’s chief financial officer, said: “This non-dilutive capital strengthens our balance sheet by adding gross cash proceeds of $150 million, supporting continued investment in our strategic priorities, which include executing the commercial launches of Miplyffa and Olpruva (sodium phenylbutyrate), and advancing our pipeline of product candidates to address unmet needs within the rare disease community.”